Implanted sensor could detect worsening heart failure before symptoms appear

A tiny implanted sensor being evaluated in an international clinical trial could give physicians an earlier warning that a patient’s heart failure is worsening — potentially before the patient realizes anything is wrong.

BayCare’s Morton Plant Hospital in Florida recently became the first site to implant an investigational heart-failure monitoring system as part of the international FUTURE-HF2 clinical trial.

The technology is designed to continuously monitor changes associated with fluid buildup, one of the major problems experienced by people living with heart failure.

The miniature sensor is implanted in the inferior vena cava, the large vein responsible for returning blood from the lower body to the heart.

Once implanted, the device measures pressure inside the vein.

Patients can take readings from home, allowing information to be transmitted to their healthcare team without requiring a hospital or clinic visit.

That could provide clinicians with an important early-warning system.

When the heart cannot pump effectively, fluid can begin accumulating in the body. Patients may eventually experience shortness of breath, swelling, fatigue and rapid weight gain.

But physiological changes can begin before those symptoms become obvious.

By identifying increasing venous pressure earlier, physicians may be able to adjust medications or other treatment before a patient’s condition deteriorates enough to require hospitalization.

Reducing hospital admissions is particularly important in heart failure, where patients frequently experience repeated episodes of worsening disease.

Implantable monitoring technologies are therefore becoming an increasingly important area of cardiovascular medicine.

Rather than relying primarily on symptoms, weight changes and periodic clinical examinations, these systems can provide physicians with physiological information while patients go about their normal lives.

The investigational system being studied in FUTURE-HF2 could potentially extend that approach by using the inferior vena cava as a location for monitoring changes in cardiovascular pressure.

Researchers will evaluate the safety and effectiveness of the technology and whether information generated by the implant can help clinicians improve heart-failure management.

The device remains investigational, and its participation in a clinical trial does not mean it has received authorization for widespread clinical use.

If successful, however, technologies like this could contribute to a larger shift in chronic disease management — from responding to deterioration after symptoms appear to detecting physiological changes early enough to intervene.

The post Implanted sensor could detect worsening heart failure before symptoms appear appeared first on Hospital News.